Has Michael Lobatz, MD received payments from drug or device companies?

Yes. Drug and device makers reported $1,659 in general payments to Michael Lobatz, MD across 71 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Michael Lobatz, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Michael Lobatz, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Michael Lobatz, MD

Neurology · Carlsbad, CANPI 1619912078

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 94.8% of the total across 71 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 14.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,115 and has fallen 93.6% since, to $71 in 2023.

$1,659in general payments, 2019–2025

Across 71 payments — averaging $23.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Amgen$242
AstraZeneca$140
AbbVie$110
Merz North America, Inc.$103
Medtronic$95
Avanir Pharmaceuticals, Inc.$89
plus $882 from 25 others

What the payments were for

Speaking & faculty fees$241%
Food & beverage$1,57395%
Education$624%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Amgen(2 entities)	7	$242
AstraZeneca	2	$140
AbbVie	6	$110
Merz North America, Inc.	4	$103
Medtronic(2 entities)	2	$95
Avanir Pharmaceuticals, Inc.	2	$89
Boston Scientific	2	$87
Biogen	4	$83
Teva Pharmaceuticals USA, Inc.	2	$73
Sanofi	5	$68
Upsher-smith Laboratories LLC	4	$62
Eisai Inc.	3	$52
Greenwich Biosciences, Inc.	3	$51
GE HealthCare	2	$43
Amneal Pharmaceuticals LLC	3	$39
Aquestive Therapeutics, Inc.	2	$32
Promius Pharma LLC	2	$28
Kyowa Kirin, Inc.	2	$28
Tersera Therapeutics LLC	2	$27
Neurocrine Biosciences, Inc.	1	$24
Acorda Therapeutics, Inc	1	$24
Novartis	1	$22
Argenx US, Inc.	1	$19
Lundbeck LLC	1	$18
Arbor Pharmaceuticals, Inc.	1	$17
Tanabe Pharma America, Inc.	1	$16
CSL Behring	1	$16
Portola Pharmaceuticals, LLC	1	$15
Zyla Life Sciences, Inc.	1	$13
Supernus Pharmaceuticals, Inc.	1	$12
Scilex Pharmaceuticals Inc.	1	$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

UPLIZNA$119

How this compares

$1,659 in reported general payments places this provider in the 55th percentile of 1,996 neurology providers in California.

See all neurology providers in California →

Medicare billing

Part B allowed, 2024

$7,918

Medicare patients

Services billed

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Gabapentin	12	$266
Donepezil Hcl	12	$226

Paid to pharmacies, not to this prescriber.

Other neurology in Carlsbad

Andrew BlumenfeldCarlsbad$4.9M
Jack SchimCarlsbad$1.7M
Benjamin FrishbergCarlsbad$1.2M
Brian DrokerCarlsbad$361K
Bilal ChoudryCarlsbad$271K
Khashayar DashtipourLoma Linda$3.3M
Regina BerkovichWest Hollywood$3M
Daniel BandariNewport Beach$2.6M
Perry ShiehLos Angeles$2.4M
Sandeep ThakkarIrvine$2M

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →